erlotinib
Showing 26 - 50 of 325
NSCLC, Carcinoma, Small Cell Lung, Carcinoma, Thymic Trial run by the National Cancer Institute (NCI) (AZD6244, MK-2206,
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- AZD6244
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)
Recruiting
- Rare Tumor
- Refractory Tumor
- Gefitinib
- +11 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Feb 16, 2022
NSCLC Trial in Badalona, Málaga (Docetaxel, Cisplatin, Gemcitabine)
Completed
- Non-small Cell Lung Cancer
- Docetaxel
- +3 more
-
Badalona, Barcelona, Spain
- +1 more
Jun 8, 2022
NSCLC Trial in Canada, United States (Nivolumab, Gemcitabine, Cisplatin)
Completed
- Non-small Cell Lung Cancer
- Nivolumab
- +8 more
-
Los Angeles, California
- +11 more
Sep 20, 2021
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Amsterdam (gemcitabine, erlotinib, metformin)
Completed
- Locally Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer
- gemcitabine
- +3 more
-
Amsterdam, NetherlandsAcademic Medical Center
Apr 19, 2021
Metastatic Breast Cancer Trial in United States (Fulvestrant, erlotinib, Placebo)
Cancer, Non Small Cell Lung Cancer Trial in Salt Lake City (PET Imaging, Erlotinib, Bevacizumab)
Completed
- Cancer
- Non Small Cell Lung Cancer
- PET Imaging
- +2 more
-
Salt Lake City, UtahHuntsman Cancer Institute
Dec 16, 2021
Brain Cancer Trial in Basking Ridge, Commack, New York (erlotinib, Cytoreductive Surgery)
Completed
- Brain Cancer
- erlotinib
- Cytoreductive Surgery
-
Basking Ridge, New Jersey
- +3 more
Jan 6, 2021
Lung Tumor Trial in São Paulo (Alectinib, Pembrolizumab, Nivolumab)
Active, not recruiting
- Lung Neoplasm
- Alectinib
- +3 more
-
São Paulo, BrazilHospital Municipal Vila Santa Catarina
Oct 5, 2021
NSCLC Trial in Netherlands (erlotinib plus docetaxel or pemetrexed, erlotinib)
Completed
- Carcinoma, Non-Small-Cell Lung
- erlotinib plus docetaxel or pemetrexed
- erlotinib
-
Amsterdam, Netherlands
- +13 more
Sep 25, 2020
Neuroendocrine Tumors Trial in San Francisco (RAD001, erlotinib)
Terminated
- Neuroendocrine Tumors
- RAD001
- erlotinib
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 27, 2020
Non Small Cell Lung Cancer Trial in United States (Stereotactic Radiosurgery, Erlotinib)
Completed
- Non Small Cell Lung Cancer
- Stereotactic Radiosurgery
- Erlotinib
-
San Francisco, California
- +7 more
Dec 17, 2020
Polycythemia Vera Trial in Oklahoma City (Erlotinib)
Terminated
- Polycythemia Vera
- Erlotinib
-
Oklahoma City, OklahomaUniversity of Oklahoma Health Sciences Center
Aug 7, 2020
Non-squamous NSCLC Trial in Italy (Erlotinib, Bevacizumab)
Active, not recruiting
- Non-squamous Non-small Cell Lung Cancer
- Erlotinib
- Bevacizumab
-
Carpi, MO, Italy
- +54 more
Mar 3, 2021
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Cancer, Advanced Solid Tumors Trial in Amsterdam (Sunitinib, Sorafenib, Erlotinib)
Completed
- Cancer
- Advanced Solid Tumors
- Sunitinib
- +9 more
-
Amsterdam, NetherlandsVUMedical Center
Apr 14, 2021
NSCLC Stage IIIA Trial in Guangzhou (Almonertinib, Erlotinib, Cisplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Stage IIIA
- Almonertinib
- +4 more
-
Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou Medical University
Jun 30, 2020
Advanced Cancer Trial in Houston (Bevacizumab, Sorafenib, Erlotinib)
Completed
- Advanced Cancer
- Bevacizumab
- +6 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 27, 2020
NSCLC Trial in United States (Erlotinib, Hydroxychloroquine)
Unknown status
- Non-small Cell Lung Cancer
- Erlotinib
- Hydroxychloroquine
-
Stanford, California
- +3 more
Jul 1, 2020
Advanced Solid Tumor, NSCLC, Colorectal Cancer Trial in Australia, United States (LY3499446, Abemaciclib, Cetuximab)
Terminated
- Advanced Solid Tumor
- +2 more
- LY3499446
- +4 more
-
Indianapolis, Indiana
- +5 more
Oct 27, 2021